A phase II study of BAT8006 for the treatment of subjects with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer
Latest Information Update: 31 Mar 2024
At a glance
- Drugs BAT 8006 (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
Most Recent Events
- 31 Mar 2024 New trial record
- 25 Mar 2024 According to Bio-Thera Solutions media release, the company announced the IND clearance from the US FDA to initiate this study.